This site contains materials related to Novo Nordisk scientific presentations at the Advanced Technologies & Treatments for Diabetes (ATTD) 2020 congress. The information on this site is intended for Healthcare Providers only and may relate to data concerning study drugs or therapeutic uses that have not been approved by drug regulatory agencies. The information contained in this site is not intended to promote in any way, any use, either approved, or unapproved, of a Novo Nordisk product or of any other product. Furthermore, it is not intended to replace the advice of a healthcare professional and should not be construed as providing advice or making a recommendation.

The information on this site should not be relied on as the basis for any decision or action. Only a physician can determine whether a specific product is correct for a particular patient. If you have any questions regarding any information contained on this site you should consult a physician.

Novo Nordisk accepts no liability for the accuracy, completeness or use of this information, and disclaims any liability to update the information contained on this website.

I have read and accept the legal notice for Novo Nordisk scientific presentations at ATTD 2020.

 Accept  Decline

Relationship between HbA1c and hypoglycaemia risk in adults with type 2 diabetes treated with IDegAsp OD/BID versus insulin glargine U100 OD plus insulin aspart OD/BID/TID

Y Gupta,1 T Demir,2 S Dey,3 B Kalyanam,4 L Liu,5 U Pedersen-Bjergaard,6 A Philis-Tsimikas7

1Department of Endocrinology, All India Institute of Medical Sciences, New Delhi, India; 2Dokuz Eylul University Medical School, Department of Internal Medicine, Izmir; Turkey; 3Global Development GSC, Novo Nordisk Service Centre India Private Ltd; Bengaluru, India; 4Global Medical Affairs, Novo Nordisk Service Centre India Private Ltd; Bengaluru, India; 5Medical & Science, Global Development, Novo Nordisk A/S, Søborg, Denmark; 6Department of Clinical Medicine, Nordsjællands Hospital - Hillerød, Denmark; 7Scripps Whittier Diabetes Institute, San Diego, CA, USA

 

Watch our video

Relationship between HbA1c and hypoglycaemia risk in adults with type 2 diabetes treated with IDegAsp OD/BID versus insulin glargine U100 OD plus insulin aspart OD/BID/TID

View Presentation

 

View Presentation

Video

Presentation Slides

References
(1) Davies et al. Diabetologia 2018;61:2461–98;
(2) Stratton et al. BMJ 2000;321:405–12;
(3) Shetty et al. J Manag Care Pharm 2005;11:559–64;
(4) Giugliano et al. Diabetes Care 2011;34:510–7;
(5) Sakane et al. J Diabetes Investig 2015;6:567–70;
(6) Peyrot et al. Diabetic Med 2012;29:682–9;
(7) Khunti et al. Diabetes Obes Metab 2018;20:427–37.